# GridAI Technologies Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/GridAI Technologies Corp.). ## Overview GridAI Technologies Corp. is a U.S.-based biotechnology company that develops targeted, non-systemic therapies for gastrointestinal diseases, with product candidates including Adrulipase, Niclosamide, Capeserod, and Latiglutenase. In September 2025 it also acquired Grid AI Corp., adding an AI-driven grid-edge software and device platform for utilities, energy retailers, and large commercial and industrial customers to its operations. ## Products & services • Adrulipase GI therapy development program • Niclosamide gastrointestinal product candidate • Capeserod in-licensed GI asset • Latiglutenase GI product candidate • Grid AI / AmpX energy orchestration platform • AI-based distributed energy resource optimization - **GI drug development programs** (85%) — Non-systemic therapeutic candidates designed to act locally in the gastrointestinal tract. - **In-licensed clinical assets** (10%) — Externally sourced drug programs, including Capeserod, that expand the pipeline. - **Grid AI software and device platform** (5%) — AI-driven energy orchestration tools for utilities and large power users. - Adrulipase targeted non-systemic GI therapy - Niclosamide product candidate for GI indications - Capeserod in-licensed GI asset from Sanofi - Latiglutenase GI product candidate - Grid AI / AmpX grid-edge orchestration platform - AI software for load management and DER optimization ## Customers The biotechnology side of the business is not yet commercial, so its end customers are future patients and the physicians, hospitals, and payers that would adopt approved GI therapies. The newly acquired Grid AI business sells to utilities, energy retailers, and large commercial and industrial customers that need software to manage distributed energy resources and optimize power usage. Until products are commercialized, the company is primarily funded by capital markets rather than customer revenue. - **Future GI therapy patients and providers** (primary) — Would buy or prescribe approved non-systemic GI treatments such as Adrulipase and Capeserod for localized disease management. - **Utilities** (secondary) — Buy Grid AI software to coordinate distributed energy resources, improve reliability, and manage grid conditions. - **Energy retailers** (secondary) — Use the platform to optimize load, integrate on-site assets, and support customer energy programs. - **Commercial and industrial customers** (secondary) — Adopt the platform to automate load management and reduce operating costs through better energy coordination. - Future GI patients if Adrulipase and other candidates are approved - Physicians and healthcare systems that would prescribe or adopt therapies - Utilities seeking automated load and DER coordination - Energy retailers managing distributed and behind-the-meter assets - Large commercial and industrial customers optimizing power usage ## Geography The company is headquartered in the United States and its reported operations and financing activity are primarily U.S.-based. No country-level revenue disclosure was provided, and the business remains pre-revenue, so geographic exposure is driven more by where development, financing, and any future commercialization occur than by current sales. The Grid AI acquisition may broaden exposure into utility and industrial energy markets, but the filing does not yet provide a regional revenue split. - Headquartered in the United States - No disclosed country-level revenue because the company is pre-revenue - Development and financing activity are primarily U.S.-based - Grid AI may expand exposure to utility and industrial energy markets - Geographic risk is currently more funding-related than sales-related ## Strategy The core strategy remains advancing GI drug candidates while preserving optionality through in-licensing and acquisitions. The Grid AI acquisition adds a second operating track in energy technology, which could diversify the company if integration succeeds, but near-term execution still depends on financing, development progress, and regulatory milestones. - **Fund the business through equity and debt financing** (short-term) — The company has no revenue and needs capital to support development and operations. - **Advance GI pipeline assets** (medium-term) — Clinical progress is required to create value from the biotechnology business. - **Integrate Grid AI and AmpX** (medium-term) — The acquisition could create a second growth platform and broaden the company’s business model. - Advance Adrulipase and other GI candidates toward clinical progress - Use in-licensing to expand the clinical pipeline - Pursue acquisitions and partnerships to add assets and capabilities - Integrate Grid AI and AmpX as a new operating component - Raise capital to fund development, operations, and potential commercialization ## Risks The company remains a pre-revenue, development-stage business with substantial going-concern risk and dependence on external financing. It also faces execution risk from clinical development, regulatory approval, and the integration of a newly acquired energy technology platform that is outside its historical biotech focus. - **Going-concern and liquidity risk** [critical] — The company has no revenue, recurring losses, and limited cash, so it must raise capital to continue operations. - **Clinical development failure** [high] — Pipeline value depends on successful trials and regulatory approvals for Adrulipase and other candidates. - **Integration risk from Grid AI acquisition** [medium] — The company is adding a new energy-tech operating component that requires integration, product alignment, and execution. - **Nasdaq listing compliance risk** [medium] — The company previously received a bid-price deficiency notice, which can pressure liquidity and investor access. - No revenue yet, so operations depend on external capital - Going-concern risk if financing is not available when needed - Clinical and regulatory failure could impair pipeline value - Integration risk from the Grid AI acquisition - Nasdaq listing compliance and market-capitalization pressure ## Accounting The most important accounting issue is that the company is still pre-revenue, so reported results are dominated by R&D, G&A, financing costs, and acquisition accounting rather than product sales. Investors should also watch purchase accounting for the Grid AI acquisition, stock-based compensation, debt and convertible preferred stock instruments, and any future impairment or valuation judgments as the business mix changes. - **Pre-revenue operating model** — Makes quarterly comparisons highly sensitive to development and financing activity - **Business combination accounting** — Can affect goodwill, intangible assets, and future impairment risk - **Stock-based compensation** — Inflates operating expenses without immediate cash outflow - **Convertible preferred stock and debt** — Affects dilution, equity classification, and interest/financing expense - No revenue recognition yet because the company is pre-commercial - R&D and G&A drive reported losses and quarterly volatility - Acquisition accounting for Grid AI may create fair value estimates - Debt and preferred stock terms affect dilution and balance sheet presentation - Stock-based compensation can materially affect operating expenses --- *Last updated: 2026-04-28T20:12:35.684341+00:00*